title: [Conjugated vaccines].
abstract: Encapsulated bacterial pathogens (e.g. Haemophilus influenzae type b [Hib], Neisseria meningitidis, or Streptococcus pneumoniae) target infants and young children who have lost any protective anti-capsular antibodies supplied maternally and whose immune systems are ineffective against T-independent antigens such as the polysaccharides of the capsule. The polysaccharide-protein conjugate vaccines overcome this limitation by converting the polysaccharide to a T-dependent antigen, which allows a vaccinated infant to mount a protective immune response. Where conjugated vaccines have been introduced into paediatric vaccination schedules, the incidence of invasive diseases caused by Hib, the group C meningococcus, or the pneumococcus has plummeted by at least 80%, a major public health success. Furthermore, surveillance has demonstrated that the conjugate vaccines provide 'herd protection' through their beneficial impact on nasopharyngeal colonisation among vaccinated children. Promising future approaches include enhancement of the number of capsular serogroups targeted by the meningococcal or pneumococcal conjugate vaccines.
authors.affiliation: International Scientific & Clinical Affairs, Wyeth Vaccines, La Défense, Paris, France. fritzeb@wyeth.com
authors.forename: Bernard
authors.initials: B
authors.lastname: Fritzell
mesh_terms: D018073:Haemophilus Vaccines; D019741:Haemophilus influenzae type b / Q000276:immunology; D006801:Humans; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology; D013296:Streptococcus pneumoniae / Q000276:immunology; D018074:Vaccines, Conjugate / Q000627:therapeutic use*
chemical_list: D018073:Haemophilus Vaccines; D018074:Vaccines, Conjugate